RxDoctor Payments Data

Samuel Friedman, MD

Hematology & Oncology · Tamuning, GUNPI 1891747069

Payments from drug & device makers

$543in general payments, 2019–2025

Across 17 payments — averaging $31.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$308
  • Amgen$93
  • Seagen Inc.$63
  • Karyopharm Therapeutics Inc.$38
  • GSK$22
  • Tempus AI, Inc$19

What the payments were for

  • Speaking & faculty fees$15028%
  • Food & beverage$39372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)5$308
Amgen5$93
Seagen Inc.3$63
Karyopharm Therapeutics Inc.2$38
GSK1$22
Tempus AI, Inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Guamto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,005,944
Medicare patients
199
Services billed
125,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RetevmoSelpercatinib16$155,201
JardianceEmpagliflozin11$11,343
Abiraterone Acetate77$6,297
Amlodipine Besylate104$973
Imatinib Mesylate12$869
Novolin NInsulin Nph Human Isophane15$767
Allopurinol59$760
Atorvastatin Calcium56$613
Rosuvastatin Calcium30$516
Glipizide35$515
Dexamethasone67$506
Metformin Hcl40$475
Losartan Potassium45$451
Hydroxyurea11$348
Prednisone23$263

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Tamuning

Where these figures come from

Is this you, or does something look wrong? →